eligibility_summary
Eligible: metastatic colorectal cancer with RAS mutation, ECOG 0–1, informed consent, available tumor tissue (surgical or biopsy) and 10 mL peripheral blood. Exclude: diagnosis not confirmed by colonoscopy or metastatic biopsy, stage I–III CRC, RAS wild-type mCRC, inadequate organ function (severe blood, liver, or kidney abnormalities).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: 1) Longitudinal circulating tumor DNA (ctDNA) testing (liquid biopsy) to detect conversion from RAS-mutant to NeoRAS wild-type (WT) in metastatic colorectal cancer, 2) Cetuximab given to ctDNA-confirmed NeoRAS WT patients. Drug/mechanism: Cetuximab (C225) is a chimeric IgG1 anti-EGFR monoclonal antibody. It blocks ligand binding and EGFR activation/dimerization, promotes receptor internalization, inhibits downstream RAS–RAF–MEK–ERK and PI3K–AKT signaling, and mediates antibody-dependent cellular cytotoxicity (ADCC) via FcγR+ immune cells. Targets: EGFR on colorectal cancer cells, downstream MAPK and PI3K pathways, relies on WT RAS for efficacy, ctDNA targets tumor-derived DNA to monitor RAS status.